Cannabics Pharmaceuticals is a biotechnology business based in the US. Cannabics Pharmaceuticals shares (CNBX) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.01 – the same closing value as a week prior. Cannabics Pharmaceuticals employs 2 staff and has a trailing 12-month revenue of around $230,074.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.01 |
|---|---|
| 52-week range | $0.01 - $0.02 |
| 50-day moving average | $0.01 |
| 200-day moving average | $0.01 |
| Wall St. target price | N/A |
| PE ratio | 0.0294 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.34 |
Historical closes compared with the close of $0.01 from 2024-11-25
| 1 week (2024-11-20) | 0.01 |
|---|---|
| 1 month (2024-10-25) | 0.01 |
| 3 months (2024-08-27) | 0.01 |
| 6 months (2024-05-24) | 2.04% |
| 1 year (2023-11-27) | -19.35% |
|---|---|
| 2 years (2022-11-25) | -99.75% |
| 3 years (2021-11-26) | 16.368 |
| 5 years (2019-11-27) | 15.6 |
Valuing Cannabics Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cannabics Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cannabics Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Cannabics Pharmaceuticals shares trade at around 0x recent earnings.
However, Cannabics Pharmaceuticals's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
| Revenue TTM | $230,074 |
|---|---|
| Gross profit TTM | $7,157 |
| Return on assets TTM | -116.59% |
| Return on equity TTM | -4289.36% |
| Profit margin | 0% |
| Book value | $-0.08 |
| Market Capitalization | $311,114 |
TTM: trailing 12 months
We're not expecting Cannabics Pharmaceuticals to pay a dividend over the next 12 months.
You may also wish to consider:
Cannabics Pharmaceuticals's shares were split on a 1:120 basis on 11 May 2022 . So if you had owned 120 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cannabics Pharmaceuticals shares – just the quantity. However, indirectly, the new 11900% higher share price could have impacted the market appetite for Cannabics Pharmaceuticals shares which in turn could have impacted Cannabics Pharmaceuticals's share price.
Over the last 12 months, Cannabics Pharmaceuticals's shares have ranged in value from as little as $0.005 up to $0.0184. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Cannabics Pharmaceuticals's is 0.793. This would suggest that Cannabics Pharmaceuticals's shares are less volatile than average (for this exchange).
To put Cannabics Pharmaceuticals's beta into context you can compare it against those of similar companies.
CNBX Pharmaceuticals Inc. , a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.